Diabetes and vessel wall remodelling: From mechanistic insights to regenerative therapies

IRCCS Multimedica, Milan, Italy.
Cardiovascular Research (Impact Factor: 5.94). 06/2008; 78(2):265-73. DOI: 10.1093/cvr/cvn039
Source: PubMed


Over the past two decades, extensive research has focused on arterial remodelling in both physiological and pathological ageing. The concept now describes the growth as well as the rearrangement of cellular components and extracellular matrix, resulting in either reduction or increase in vessel lumen. In diabetes, remodelling extends to capillaries, microvascular beds, and arteries of different calibre. This process is paralleled by accelerated atherosclerosis and accounts for an increased incidence of ischaemic complications. The incapacity of pre-existing and de novo formed collaterals to bypass atherosclerotic occlusions, combined with a decline in tissue capillary density, is responsible for the delayed recovery from ischaemia and ultimately leads to organ failure. The mechanisms of vascular remodelling are incompletely understood, but metabolic and mechanical factors seem to play an important role. Hyperglycaemia represents the main factor responsible for the fast progression of atherosclerosis as well as microangiopathy. However, intensive blood glucose control alone is insufficient to reduce the risk of macrovascular complications. Pharmacological control of oxidative stress and stimulation of nitric oxide release have proved to exert beneficial effects on vascular remodelling in experimental diabetic models. New approaches of regenerative medicine using vascular progenitor cells for the treatment of ischaemic disease have been shown to be safe and are now being tested for efficacy in pre-clinical and clinical trials.

Download full-text


Available from: Gaia Spinetti,
  • Source
    • "Increased EPC migration induced via VEGF was observed in the control group as compared to the diabetic groups [19]. Some authors have observed an inverse correlation between glycated hemoglobin and the number of endothelial progenitor cells [17] [18] [24]. Churdchomjan et al. published their study " Comparison of endothelial progenitor cell function in type 2 diabetes with good and poor glycemic control compare EPC function in type 2 diabetes with good and poor glycemic control " [14] "
    [Show abstract] [Hide abstract]
    ABSTRACT: In the late 20th century endothelial progenitor cells (EPCs) were discovered and identified as cells capable of differentiating into endothelial cells. Antigens characteristic of endothelial cells and hematopoietic cells are located on their surface. EPCs can proliferate, adhere, migrate and have the specific ability to form vascular structure, and they have a wide range of roles: They participate in maintaining hemostasis, and play an important part in the processes of vasculogenesis and angiogenesis. They are sources of angiogenic factors, especially vascular endothelial growth factor (VEGF). EPCs exist in bone marrow, from which they are recruited into circulation in response to specific stimuli. Tissue ischemia is thought to be the strongest inductor of EPC mobilization. Local ischemia accompanies many pathological states, including diabetic foot syndrome (DFS). Impaired angiogenesis--in which EPCs participate--is typical of DFS. An analysis of the available literature indicates that in diabetic patients the number of EPCs declines and their functioning is impaired. Endothelial progenitor cells are crucial to vasculogenesis and angiogenesis during ischemic neovascularization. The pathomechanisms underlying impaired angiogenesis in patients with DFS is complicated, but the discovery of EPCs has shed new light on the pathogenesis of many diseases, including diabetes foot syndrome.
    Advances in Clinical and Experimental Medicine 03/2012; 21(2):249-54. · 1.10 Impact Factor
  • Source
    • "Normal endothelium produces nitric oxide (NO) and prostacyclin which inhibit platelet activation under physiological conditions. Endothelial dysfunction leads to reduced production on NO and prostacyclin and so contributes to platelet hyperreactivity [54, 55]. NO can be oxidized by superoxide anions, leading to further reductions in its half-life and antiplatelet action [52]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients with diabetes mellitus have an increased prevalence of vascular disease. Pathologic thrombosis associated with atherosclerotic plaque rupture is a major cause of morbidity and mortality. Platelets are intimately involved in the initiation and propagation of thrombosis. Evidence suggests that platelets from patients with type 2 diabetes have increased reactivity and baseline activation compared to healthy controls. We review the pathophysiology of platelet hyperreactivity in DM patients and its implications in clinical practice, with particular focus on acute coronary syndromes, percutaneous coronary intervention, and novel antiplatelet agents.
    International Journal of Endocrinology 08/2011; 2011(1687-8337):742719. DOI:10.1155/2011/742719 · 1.95 Impact Factor
  • Source
    • "Indeed, hyperglycemia, associated with endothelial dysfunction and reduced new blood vessel growth, is a primary cause of vascular complications in diabetes [32]. Moreover, diabetic patients show lower levels of circulating EPC with reduced proliferation , adhesion, and migration capacities compared to healthy subjects [33] [34] [35]. Impaired in vivo reendothelization capacity of EPC from patients with diabetes is mediated by oxidant stress and reduced NO bioavailability [36]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Peripheral arterial disease (PAD) is a major health problem especially when associated to concomitant diabetes and hypercholesterolemia. Hyperglycemia with an overwhelming generation of oxygen radicals and formation of glycation end-products exacerbates oxidation-sensitive mechanisms activated by tissue ischemia. Administration of autologous bone marrow cells (BMC) is an increasing notable intervention to induce therapeutic angiogenesis, ameliorated by metabolic intervention (MT). Recently, hemangioblasts (HS) with functional properties were isolated. The effects of integrate regimen with intravenous BMC, HS, and MT (1.0% vitamin E, 0.05% vitamin C, and 6% l-arginine) were examined in the ischemic hindlimb of ApoE(-/-) diabetic and non-diabetic. Blood flow ratio was monitored by use of a laser Doppler blood flowmeter. Capillary density was determined in sections of the adductor and semimembranous muscles with antibody against CD31. BMC or HS alone, and BMC plus HS increased blood flow and capillary densities and decreased interstitial fibrosis. These effects were amplified by additional MT, at least in part, through the nitric oxide pathway, reduction of systemic oxidative stress and macrophage infiltration. Investigation of molecular mechanisms in bone marrow (BM)-derived progenitor cells from mice revealed that BMC therapy and, more consistently, in combination with MT ameliorated functional activity via decreased cellular senescence and increased telomerase and chemokine CXCR4 activities. Telomerase activity was also increased by HS alone or HS+MT and, more consistently, by BMC+HS alone or in combination with MT. Intravenous autologous BMC and HS intervention together with MT increased therapeutic angiogenesis in the ApoE(-/-) diabetic mouse hindlimb.
    Atherosclerosis 10/2009; 209(2):403-14. DOI:10.1016/j.atherosclerosis.2009.10.022 · 3.99 Impact Factor
Show more